The front page of AI-driven biology
Thursday, October 15, 2026Thu, Oct 15
Updated 8:01 PM PT
Akeso and Summit Therapeutics reported that their bispecific antibody targeting PD-1 and VEGF extended median overall survival to 30.8 months compared with 22.6 months for pembrolizumab in the Phase 3 HARMONi-2 trial in non-small cell lung cancer.
Novartis lost roughly $30 billion in market value after delpacibart etedesiran failed to beat placebo on hand opening time at 54 weeks in the Phase 3 HARBOR trial for myotonic dystrophy type 1. The drug is an antibody-oligonucleotide conjugate, designed to deliver siRNA to muscle cells via the transferrin receptor 1, which Novartis acquired in its $12 billion buyout of Avidity Partners.
The B7-H3-directed antibody-drug conjugate risvutatug rezetecan reached a median overall survival of 18.5 months versus 10.3 months for topotecan chemotherapy in a Phase 3 study of relapsed small-cell lung cancer.
Adding the kinase inhibitor zipalertinib to platinum-based chemotherapy extended median progression-free survival to 14.5 months compared to 8.5 months for chemotherapy alone in previously untreated non-small cell lung cancer with EGFR exon 20 insertion mutations.
BioNTech's gotistobart, an antibody targeting the immune checkpoint CTLA-4, reached a median overall survival of 18.5 months versus 10 months for docetaxel chemotherapy in patients with relapsed squamous non-small cell lung cancer.
Definium Therapeutics reported that its single-dose oral LSD formulation, DT120 ODT, met the primary endpoint of the 245-patient Phase 3 Panorama trial in generalized anxiety disorder.
A combination of Amgen's T-cell engager Imdelltra (tarlatamab) and AstraZeneca's checkpoint inhibitor Imfinzi prolonged overall survival compared to Imfinzi alone in untreated, extensive-stage small-cell lung cancer.
Novo Nordisk reported that 40% of pediatric participants receiving the GLP-1 receptor agonist Wegovy (semaglutide) were no longer classified as having obesity in a Phase 3 pediatric trial.
Amgen's bispecific T-cell engager Imdelltra (tarlatamab), which targets DLL3 to direct immune cells against tumors, demonstrated a statistically significant improvement in overall survival in a first-line small-cell lung cancer trial.